SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives
ACS Omega · 16.09.2025 · 10 (36) · 41608-41619
DOI: 10.1021/acsomega.5c05168 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 27.08.2025. Verfasst von Kohei Tsuji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiy…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University Fellowship Creation Project for Creating Scientific and Technological Innovation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Development of anti-SARS-CoV-2 agents is still required because of the appearance of drug-resistant strains, and targeting the main protease (Mpro) of SARS-CoV-2 is a powerful way to develop therapeutics against COVID-19. To date, we have developed several Mpro inhibitors including compounds 3, 4, TKB245 (6), and TKB248 (7), which have a 4-fluorobezothiazole ketone moiety as a warhead structure. Further studies led to the development of a more potent Mpro inhibitor, TKB272 (8), which has a 5-fluorobenzothiazole ketone moiety. The slight difference in the introduction position of a fluorine atom enhanced its antiviral activity approximately 3-fold for VeroE6 cells and 15-fold for HeLahACE2‑TMPRSS2 cells when TKB272 (8) was compared to TKB245 (6). Herein, we report the synthesis and structure-activity relationship (SAR) studies of TKB272 (8). TKB272 (8) is a promising drug candidate for COVID-19 therapy, and the present data of the SAR studies are useful for the further development of Mpro inhibitors.
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiyoda-ku 101-0062, Tokyo, Japan.
- Department of Refractory Viral Infections, National Institute of Global Health and Medicine, Japan Institute for Health Security, Shinjuku-ku 162-8655, Tokyo, Japan.
- Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
- Department of Clinical Sciences, Kumamoto University Hospital, Chuo-ku 860-8556, Kumamoto, Japan.
ORCID-Profile: Kohei Tsuji, Nobuyo Higashi-Kuwata, Takahiro Ishii, Hirokazu Tamamura
Förderung
- University Fellowship Creation Project for Creating Scientific and Technological Innovation
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Support for Pioneering Research Initiated by the Next Generation
Zitieren
APA
Tsuji, K., Kobayakawa, T., Higashi-Kuwata, N., Ishii, T., Shinohara, K., Yamamoto, R., Miura, Y., Wada, N., Mitsuya, H., & Tamamura, H. (2025). SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives. ACS Omega, 10(36), 41608-41619. https://doi.org/10.1021/acsomega.5c05168
Vancouver
Tsuji K, Kobayakawa T, Higashi-Kuwata N, Ishii T, Shinohara K, Yamamoto R, et al. SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives. ACS Omega. 2025;10(36):41608-41619. doi:10.1021/acsomega.5c05168
BibTeX
@article{Tsuji2025,
author = {Tsuji, Kohei and Kobayakawa, Takuya and Higashi-Kuwata, Nobuyo and Ishii, Takahiro and Shinohara, Kouki and Yamamoto, Ryusei and Miura, Yutaro and Wada, Naoya and Mitsuya, Hiroaki and Tamamura, Hirokazu},
title = {SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives},
journal = {ACS Omega},
year = {2025},
volume = {10},
number = {36},
pages = {41608--41619},
doi = {10.1021/acsomega.5c05168}
}
EUVIMED